MARKET

CNCR

CNCR

Loncar Cancer Immunotherapy ETF
NASDAQ

Real-time Quotes | Provided by Morningstar

28.74
-0.82
-2.77%
Closed 16:00 10/19 EDT
OPEN
29.59
PREV CLOSE
29.55
HIGH
29.59
LOW
28.66
VOLUME
8.38K
TURNOVER
--
52 WEEK HIGH
30.25
52 WEEK LOW
12.00
TOTAL ASSET
40.94M
YTD YIELD
7.47%
1D
5D
1M
3M
1Y
5Y
News
Performance
Don't buy the stock market hype around coronavirus vaccine and treatment companies
CNN.com · 5d ago
Biotech Investing In A Time Of The Coronavirus
A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.Firms are forging ahead with testing, treatment and vaccine research and product development.Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.A wise investor would be well-served by opening or adding to such positions with a measure of caution.
Seekingalpha · 10/09 16:49
BioNTech Investor Fortunes Rise and Fall on Headlines, Pacts and Funding
BioNTech (NASDAQ:BNTX) has been getting increased investor attention due to its work on vaccine development against the novel coronavirus. So far in the year, BNTX stock has almost doubled. Let's take a closer look at what investors may expect from the shares of the Mainz, Germany-headquartered firm
InvestorPlace · 09/18 09:46
Biotechnology Innovation During COVID-19
Seeking Alpha - Article · 06/11 07:47
ACADIA: The Company's Perspectives In Numbers.
Seeking Alpha - Article · 05/15 15:18
USO, UCO, LABU and ITB among weekly ETF movers
Seeking Alpha - Article · 05/01 21:13
USO, OIL, TQQQ and SQQQ among weekly ETF movers
Seeking Alpha - Article · 04/18 03:51
Will These Tech Stock Valuations Last?
Seeking Alpha - Article · 02/13 13:06
More
No Data
Learn about the latest financial forecast of CNCR. Analyze the recent business situations of Loncar Cancer Immunotherapy ETF through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
Ratings
Date
Period
Agency
Ratings
08/31/2020
3 Year
Morningstar
  • Performance
  • Asset Allocation
  • Dividend History
Period
Return
Rank in Cat
1-Month
-5.0143%
--
3-Month
-4.7065%
--
6-Month
14.1693%
--
1-Year
7.4707%
--
3-Year
-0.4919%
--
Since Inception
0.5594%
--
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Profile
Fund Name
Loncar Cancer Immunotherapy ETF
Risk
Low risk
Inception Date
2015-10-13
Benchmark
Dow Jones US Healthcare TR
Advisor Company
Loncar Investments
Custodian
U.S. Bank N.A
Manager
Wen/Zayas